Course syllabus

Drug Development BIO523

 Programs:                  Molecular Biology and Genomics/Systems Biology programs (GU), Biotechnology program (Chalmers)

Place in program:     Year 4/5, optional

Number of students: No limitation

Course leader:           Prof. Margit Mahlapuu, Department of Chemistry and Molecular Biology (CMB), Göteborg University; Medicinaregatan 9C, 413 90 Göteborg/ Box 462  405 30 Göteborg

Phone: 0706310109

E-mail: margit.mahlapuu@gu.se

 

Changes in the schedule and other messages regarding the course will be distributed through e-mail and/or posted at Canvas. Handouts will likewise be available at Canvas.

 

Length:                       7.5 ECTS

Prerequisites:            For admission to the course, approved courses of 120 credits in the field of natural science are required, of which at least 15 credits must be within the main subject molecular biology and 15 credits in the main subject chemistry or equivalent. In addition, applicants must prove their knowledge of English.

Time:                          Fall term 2022

Aim:                            This course shall focus on a building an overall understanding of the discovery and development of novel pharmaceuticals (drug discovery/development), covering a wide spectrum of target selection, lead discovery/optimization, nonclinical in vitro/in vivo safety and efficacy studies, clinical trials, and market authorization. Examples are given of existing drugs, how they have been developed, and their mechanisms of action. The course is mostly theoretical, but in certain parts, practical demonstrations can also be included. The Individual Project (see below) is mandatory part of the course.

Literature:                 Scientific review papers, a separate list will provided by individual lecturers via Canvas.

Exam:                           Written, at the end of the course (13th of January 10:00-14:45 in hall B Folkow)

Items in course:         The course is based on lectures.  

Teachers:                  

Margit Mahlapuu margit.mahlapuu@gu.se

Per Sunnerhagen per.sunnerhagen@cmb.gu.se

Nhu Phan  nhu.phan@chem.gu.se

Morten Grötli grotli@chem.gu.se

Göran Karlsson goran.karlsson@nmr.gu.se

Marc Pilon marc.pilon@cmb.gu.se

Björn Löwenadler bjorn.lowenadler@toleranzia.com

Lorna Fletcher lorna.fletcher@ventures.gu.se

Camilla Björn camilla.bjorn@ri.se

Pawel Baranczewski pawel.baranczewski@farmaci.uu.se

Thomas Lundbäck thomas.lundback@astrazeneca.com

Joakim Håkansson joakim.hakansson@ri.se

Ann-Charlotte Rosendahl ann-charlotte.rosendahl@sobrera.com

Pär Matsson par.matsson@gu.se

Emmelie Cansby emmelie.cansby@gu.se

Daniel Bojar daniel.bojar@gu.se

 

 SCHEDULE, Drug development

 

Premises

Lectures:                  

The lecture rooms are at Medicinaregatan 9 or 11, Gothenburg, as specified in the table below. Rooms are equipped with projectors.       

NMR Center: Swedish NMR Center in Gothenburg,             Medicinaregatan 5C (seminar room is just inside the main entrance).

                    

Day	Times	Room	Lecture/demonstration
M 14/11	13.00 – 14.45	294 Hamberger	Genetic model organisms: Yeast (Per Sunnerhagen, CMB, GU)
	15.00 – 16.45	294 Hamberger	Overview of the process of drug development (Margit Mahlapuu, CMB, GU)
Th 17/11	8.00 – 9.45	P2240 W Sjölander	Advanced optical microscopy as a tool in drug development (Thi Ngoc Nhu Phan, CMB, GU)
	10.00 – 11.45	P2240 W Sjölander	Transgenic mice in drug discovery and development (Margit Mahlapuu, CMB, GU)
M 21/11	13.00 – 14.45	1405 B Follow	High throughout screening: assay development, validation, and platform (Thomas Lundbäck, AstraZeneca)
	15.00 – 16.45	1405 B Follow	High throughout screening: assay development, validation, and platform (Thomas Lundbäck, AstraZeneca)
Th 24/11	8.00 – 9.45	NMR center	Protein as a target molecule: rational drug design (Göran Karlsson, NMR center, GU)
	10.00 – 11.45	NMR center	NMR-based methods in drug discovery (Göran Karlsson, NMR center, GU)
M 28/11	13.00 – 14.45	1034 I Ivarsson	Design of pharmaceuticals directed against proteins with known activity (Morten Grøtli, CMB, GU)
	15.00 – 16.45	1034 I Ivarsson	Medical device: differences compared to pharmaceuticals (Joakim Håkansson, RISE)
Th 1/12	8.00 – 9.45	1034 I Ivarsson	Peptide and protein drugs (Margit Mahlapuu, CMB, GU; Björn Löwenadler, Toleranzia)
	10.00 – 11.45	1034 I Ivarsson	Genetic model organisms: C. elegans (Marc Pilon, CMB, GU)
M 5/12	13.00 – 14.45	2256 R Sandberg	Antisense therapy (Pär Matsson, Dept. of Pharmacology, GU and OligoNova Hub, Oligonucleotide Therapeutics)
	15.00 – 16.45	2256 R Sandberg	Development of novel anti-infectives: opportunities and vulnerabilities (Camilla Björn, RISE)
Th 8/12	8.00 – 9.45	2046 N Nilsson	Intellectual property and financing aspects of early drug discovery (Lorna Fletcher, GU Ventures)
	10.00 – 11.45	via Zoom, see invite in Files	Pharmacokinetics, ADME, drug metabolism (Pawel Baranczewski, SciLifeLab, Uppsala)
M 12/12	13.00 – 14.45	294 Hamberger	New medicines: market access and customer perspective (45 min; Ann-Charlotte Rosendahl, Sobrerea) AI in drug discovery (45 min; Daniel Bojar, GU)
	15.00 – 16.45	294 Hamberger	Individual project presentations (Emmelie Cansby, GU)
Th 15/12	8.00 – 9.45	A404, Medg 8B	Individual project presentations (Emmelie Cansby, GU)
	10.00 – 11.45	A404, Medg 8B	Individual project presentations (Emmelie Cansby, GU)